Skip to content

Study · Measured the body's own peptide · 1993

6 results

Immunoreactive thymosin alpha 1 in human thymus and thymoma.

Naruse H, Hashimoto T, Yamakawa Y, Iizuka M, Yamada T, Masaoka A

The Journal of thoracic and cardiovascular surgery1 Dec 1993Cited by 5 (Europe PMC)

PMID8246540 (opens in a new tab)DOI10.1016/s0022-5223(19)33979-0 (opens in a new tab)PepBankPUB-08246540
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

No result from this study comes from a test of the peptide.

Natural levels measured6

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 01HumanEndogenous levelObservational studyOther

    Thymosin alpha‑1-like immunoreactivity was higher in thymoma tissue than in normal thymus.

    In plain wordsThe body's own thymosin alpha‑1 level was higher in thymoma tissue than in normal thymus tissue.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseThymosin alpha 1-like immunoreactivity, thymoma versus normal thymus
    Study

    n: not reported in source

    human thymus and thymoma tissue extracts
    Comparator
    Normal thymus
    Outcome group
    Immune response · Cancer

    Measurements

    Thymosin alpha 1-like immunoreactivity
    45 ng/mg protein
    normal thymuses
    Thymosin alpha 1-like immunoreactivity
    273.9 ng/mg protein
    thymomas

    Source sentences

    Summary
    The average thymosin alpha 1-like immunoreactivity level was 45.0 +/- 52.1 ng/mg protein in normal thymuses and 273.9 +/- 205.0 ng/mg protein in thymomas. The average thymosin alpha 1-immunoreactivity level in thymomas was higher than that in normal thymuses.
    1 context sentence
    Summary · context
    Thymosin alpha 1-like immunoreactivity was assessed in human thymus and thymoma tissue extracts by means of a new radioimmunoassay that included an anti-thymosin alpha 1 mouse monoclonal antibody.

    This result measures the body's own Thymosin alpha-1. Nobody was given the peptide. It is not evidence about taking it.

  2. 02HumanEndogenous levelObservational studyOther

    Thymosin alpha‑1-like immunoreactivity decreased with age in normal thymuses but not in thymomas.

    In plain wordsThe body's own thymosin alpha‑1 level fell with age in normal thymus but not in thymoma.

    Peptide
    Thymosin alpha-1
    Outcome
    MixedThymosin alpha 1-like immunoreactivity by age
    Study

    n: not reported in source

    human thymus and thymoma tissue extracts
    Outcome group
    Aging markers · Immune and inflammation

    Source sentences

    Summary
    Thymosin alpha 1-like immunoreactivity levels decreased with age in normal thymuses but not in thymomas.
    1 context sentence
    Summary · context
    Thymosin alpha 1-like immunoreactivity was assessed in human thymus and thymoma tissue extracts by means of a new radioimmunoassay that included an anti-thymosin alpha 1 mouse monoclonal antibody.

    This result measures the body's own Thymosin alpha-1. Nobody was given the peptide. It is not evidence about taking it.

  3. 03HumanEndogenous levelObservational studyOther

    Thymosin alpha‑1-like immunoreactivity in thymomas appeared to have no relationship to clinical stage or associated diseases.

    In plain wordsThe body's own thymosin alpha‑1 level in thymomas did not appear to be linked to the stage of the tumour.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changeThymosin alpha 1-like immunoreactivity versus thymoma stage
    Study

    n: not reported in source

    human thymus and thymoma tissue extracts
    Outcome group
    Immune response · Cancer

    Source sentences

    Summary
    Thymosin alpha 1-like immunoreactivity levels in thymomas appeared to have no relationship to the clinical stage of the thymoma or associated diseases.
    1 context sentence
    Summary · context
    Thymosin alpha 1-like immunoreactivity was assessed in human thymus and thymoma tissue extracts by means of a new radioimmunoassay that included an anti-thymosin alpha 1 mouse monoclonal antibody.

    This result measures the body's own Thymosin alpha-1. Nobody was given the peptide. It is not evidence about taking it.

  4. 04HumanEndogenous levelObservational studyOther

    Thymosin alpha‑1-like immunoreactivity was significantly higher in polygonal cell thymomas than in spindle cell thymoma.

    In plain wordsThe body's own thymosin alpha‑1 level was higher in polygonal cell thymomas than in spindle cell thymoma.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseThymosin alpha 1-like immunoreactivity by thymoma cell type
    Study

    n: not reported in source

    human thymus and thymoma tissue extracts
    Comparator
    Spindle cell thymoma
    Outcome group
    Immune response · Cancer

    Measurements

    Thymosin alpha 1-like immunoreactivity
    382.5 ng/mg protein
    polygonal cell thymomas
    Thymosin alpha 1-like immunoreactivity
    101.8 ng/mg protein
    spindle cell thymoma

    Source sentences

    Summary
    When viewed according to histologic characteristics, the average thymosin alpha 1-like immunoreactivity level in polygonal cell thymomas (382.5 +/- 192.6 ng/mg protein) was significantly higher than that in the spindle cell thymoma (101.8 +/- 81.2 ng/mg protein).
    1 context sentence
    Summary · context
    Thymosin alpha 1-like immunoreactivity was assessed in human thymus and thymoma tissue extracts by means of a new radioimmunoassay that included an anti-thymosin alpha 1 mouse monoclonal antibody.

    This result measures the body's own Thymosin alpha-1. Nobody was given the peptide. It is not evidence about taking it.

  5. 05HumanEndogenous levelObservational studyOther

    Thymosin alpha‑1-like immunoreactivity was higher in thymomas with predominant or moderate lymphocyte infiltration than in scant or absent ones.

    In plain wordsThe body's own thymosin alpha‑1 level was higher in thymomas with more lymphocytes.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseThymosin alpha 1-like immunoreactivity by lymphocyte infiltration
    Study

    n: not reported in source

    human thymus and thymoma tissue extracts
    Comparator
    Scant or absent lymphocyte infiltration
    Outcome group
    Immune response · Cancer

    Source sentences

    Summary
    In predominant or moderate thymomas, the average thymosin alpha 1-like immunoreactivity level was higher than that in scant or absent thymomas.
    1 context sentence
    Summary · context
    Thymosin alpha 1-like immunoreactivity was assessed in human thymus and thymoma tissue extracts by means of a new radioimmunoassay that included an anti-thymosin alpha 1 mouse monoclonal antibody.

    This result measures the body's own Thymosin alpha-1. Nobody was given the peptide. It is not evidence about taking it.

  6. 06HumanEndogenous levelObservational studyOther

    Thymosin alpha‑1-like immunoreactivity was relatively higher in thymuses of patients with myasthenia gravis than in patients with normal thymuses.

    In plain wordsThe body's own thymosin alpha‑1 level was relatively higher in the thymus of people with myasthenia gravis.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseThymosin alpha 1-like immunoreactivity in myasthenia gravis thymus
    Study

    n: not reported in source

    human thymus and thymoma tissue extracts
    Comparator
    Patients with normal thymuses
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    Also, thymosin alpha 1-like immunoreactivity levels in thymuses of patients with myasthenia gravis were relatively higher than those in patients with normal thymuses.
    1 context sentence
    Summary · context
    Thymosin alpha 1-like immunoreactivity was assessed in human thymus and thymoma tissue extracts by means of a new radioimmunoassay that included an anti-thymosin alpha 1 mouse monoclonal antibody.

    This result measures the body's own Thymosin alpha-1. Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:55 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.